Most human immunodeficiency virus type 1 (HIV-1) transmission worldwide is the result of exposure to infectious virus in genital secretions. However, current vaccine candidates are based on virus isolates from blood. In this study, vaginal secretions from HIV-1-infected women were examined for evidence of cellular viral replication that produced virus with properties different from that in blood. Multiply spliced HIV-1 messenger RNA, which is found only in cells replicating virus, was detected in all vaginal lavage samples tested. There was a strong correlation between the amounts of multiply spliced HIV-1 messenger RNA and of cell-free HIV-1 RNA in the lavage samples. In addition, significant genotypic differences were found in cell-free virus from matched blood plasma and vaginal secretions. Moreover, drug resistance-associated mutations appeared in plasma virus several months before appearing in vaginal virus. These findings indicate that cellular replication of HIV-1 occurs in vaginal secretions and can result in a virus population with important differences from that in blood.
Most human immunodeficiency virus type 1 (HIV-1) transmission worldwide is the result of exposure to infectious virus in genital secretions. However, current vaccine candidates are based on virus isolates from blood. In this study, vaginal secretions from HIV-1-infected women were examined for evidence of cellular viral replication that produced virus with properties different from that in blood. Multiply spliced HIV-1 messenger RNA, which is found only in cells replicating virus, was detected in all vaginal lavage samples tested. There was a strong correlation between the amounts of multiply spliced HIV-1 messenger RNA and of cell-free HIV-1 RNA in the lavage samples. In addition, significant genotypic differences were found in cell-free virus from matched blood plasma and vaginal secretions. Moreover, drug resistance-associated mutations appeared in plasma virus several months before appearing in vaginal virus. These findings indicate that cellular replication of HIV-1 occurs in vaginal secretions and can result in a virus population with important differences from that in blood.
Worldwide, most human immunodeficiency virus type 1 (HIV-1) infections in men have occurred through exposure to the virus in vaginal secretions [1] . In addition, most children probably have been infected through contact with HIV-1 in cervicovaginal secretions and blood during labor and delivery [2] . However, little is known about the source of HIV-1 in the female genital tract.
Studies have shown that HIV-1 proviral DNA and cell-free and cell-associated RNA are present in cervical mucus and vaginal secretions [3] [4] [5] [6] [7] [8] . The amount of HIV-1 RNA in vaginal secretions is positively correlated with that in plasma but negatively Infection, a prospective cohort study of HIV infection in the female genital tract [7] . HIV-1-infected women were eligible for enrollment in this study if they were 18-49 years old, had a Pap smear with normal results within the previous 12 months, were expected to live at least 1 year, and were receiving no antiretroviral therapy or had been using the same antiretroviral for at least 3 months before enrollment. Exclusion criteria were as described elsewhere [7] . Participants were requested to refrain from vaginal intercourse and use of intravaginal medications for 72 h before their examinations.
Sample selection. For this analysis, samples from study participants with detectable plasma virus loads were selected. In addition, to examine the correlation of multiply spliced (MS) HIV-1 mRNA and cell-free HIV-1 RNA, we selected 8 matched samples of PBMC and vaginal cells from 7 HIV-1-infected women, including 4 with a vaginal HIV-1 RNA level !100,000 copies per lavage and 3 with an HIV-1 RNA level 1100,000 copies per vaginal lavage. For the genotypic analyses, we selected blood plasma, vaginal lavage, and cervical mucus samples from 7 HIV-1-infected women, to represent a broad clinical spectrum of CD4 ϩ T lymphocyte counts and genital tract virus loads. For drug resistance-associated genotypic analysis, serial blood and lavage samples were chosen from 3 women who had been followed up for 16 months and had detectable plasma HIV-1 RNA while receiving antiretroviral therapy. To compare ratios of vaginal and plasma hepatitis C virus (HCV) to HIV-1, we used samples from 4 women who had measurable HCV RNA in plasma. To measure the amount of HIV-1 RNA in vaginal secretions due to blood contamination, we used samples from the first examinations of all 15 women who provided data for this analysis.
Specimen collection. Clinical examinations were not scheduled during menstruation, to reduce the risk of blood contamination in vaginal lavage and cervical mucus samples. At each clinical examination, we tested vaginal secretions for the presence of seminal fluid, using an acid-phosphatase assay [12] . A vaginal lavage sample subsequently was obtained by introducing 10 mL of PBS into the vagina and by collecting the pooled fluid in the posterior vaginal fornix, taking care to avoid the cervix. A cervical mucus sample then was obtained by gently inserting a cytobrush into the cervical os and slowly rotating it through a 90Њ arc before removing it and placing it in 300 mL of PBS. Endocervical swab samples were obtained to culture Neisseria gonorrhoeae and Chlamydia trachomatis and to prepare Gram's-stained smears to detect cervicitis. The vaginal lavage and cervical mucus samples were kept on ice until processed. In addition, ∼8 mL of venous blood was collected in a vacutainer tube (CPT; Becton Dickinson) that contained acid citrate dextrose anticoagulant. Specimens were taken to the laboratory within 3 h for same-day processing. Methods for processing samples, assaying for blood contamination, and extracting RNA were as described elsewhere [7, 13] .
RT-polymerase chain reaction (RT-PCR) of MS HIV-1 mRNA.
RT-PCR to detect MS HIV-1 mRNA was performed with the primer pair originally described by Saksela et al. [14] . These primers specifically amplify a 131-bp product that spans an RNA splice-donor/acceptor region in MS HIV-1 mRNA. PCR conditions were as described elsewhere [14] .
The MS PCR products were electrophoresed on a 10% polyacrylamide gel and were blotted onto a nylon membrane. The membrane was hybridized with a digoxigenin (DIG)-labeled oligonucleotide probe (DIG-5 -CG CTG TCT CCG CTT CTT CCT  GCC AT-3 ) , using standard techniques, as reported elsewhere [15] . The DIG-labeled probe bound to the membrane was visualized by use of a chemiluminescence-based DIG-nucleic acid detection assay (Boehringer Mannheim), which was used according to the manufacturer's protocol. Laser densitometry of film negatives of the chemiluminescent images was used to quantify the MS PCR products blotted onto nylon membranes. Our semiquantitative method to detect MS HIV-1 mRNA could detect ∼10
Ϫ1 HIV-1-infected cell equivalents from the chronically infected cell line 8E5 ( figure 1A) .
Quantitative-competitive (QC) RT-PCR of unspliced HIV-1 RNA. QC RT-PCR was performed using primers GAG04 and GAG06, which were designed by Piatek et al. [16] and have inosines incorporated at those positions known for sequence divergence [17, 18] . Cycling conditions and analysis of PCR products were as described elsewhere [19] .
HIV-1 gp120 envelope sequence analysis. Direct sequencing of nested PCR products from the C2V3 region in the HIV-1 gp120 envelope was used to determine the major species of viral RNA in blood plasma, vaginal lavage samples, and cervical mucus and the major species of proviral DNA in PBMC. To provide an accurate representation of the predominant viral or proviral species in a sample, we generated the PCR products used for direct sequencing from у10 copies of HIV-1 RNA or proviral DNA, as determined by QC RT-PCR and QC-PCR, respectively.
Nested PCR was used to generate a 525-bp fragment for sequencing. First-round PCR amplified a 1350-bp fragment of env, using primers HIV env-13 and HIV env-12, as described elsewhere [18] . Primary PCR reactions were done using standard PCR buffer conditions, dNTP, and primer concentrations, according to the manufacturer's protocol (Roche Molecular Systems). The secondary PCR primer pairs, JH33 (5 -CTGTTIAATGGCAGICTAGC-3 ) and JH48 (5 -RATGGGAGGRGYATACAT-3 ) or JH33/M13 (5 -TGTAAAACGACGGCCAGTCTGTTIAATGGCAGICTA-GC-3 ) and JH48/M13rev (5 -AGGAAACAGCTATGACCRAT-GGGAGGRGYATACAT-3 ), generated a 525-bp fragment that spans the C2V3 region. Sequencing reactions were done on both sense and antisense DNA strands by use of direct dye primer or dye terminator cycle sequencing, according to the manufacturer's protocol (PE Applied Biosystems). Amino acid and DNA sequence alignments were performed by use of sequence analysis software (DNASIS; Hitachi Software Engineering). Phylogenetic analysis of the C2V3 nucleotide sequences was performed by using the neighbor-joining (N-J) method of the Molecular Evolutionary Genetics Analysis program (MEGA; provided by M. Nei, Institute of Molecular Evolutionary Genetics and Department of Biology, Pennsylvania State University, University Park). The pairwise nucleotide distances for the N-J phylogenetic trees were generated by use of the Kimura 2-parameter method included in the MEGA program. N-J trees were constructed using 500 bootstrap replicates. Bootstrap values у95% were shown at the branching node of a sequence cluster. Eleven unrelated HIV-1 (subtype B) C2V3 sequences served as outliers to root the N-J trees.
Prediction of cellular tropism. V3 loop-predicted positive charges !5.0 suggest that the virus is macrophage tropic, whereas positive charges у5.0 suggest that the virus is T cell tropic [20] . Amino acids at positions 11, 24, and 25 in the V3 loop, defined in this study as signature amino acids, also were used to predict cellular tropism [21] . HIV-1 drug resistance-associated RT pol gene mutations. A line probe assay (LiPA) was used to detect mutations in the RT region of the HIV-1 pol gene that are associated with resistance to nucleoside analogues [22] . In addition, resistance mutations detected by LiPA were confirmed in a subset of samples by use of direct cycle sequencing.
Quantification of blood plasma and vaginal HCV RNA. In the study of HIV-1-and HCV-infected women, HIV-1 and HCV RNA were quantified by use of the respective Roche Amplicor assays (Roche Molecular Systems). To verify that HCV can be quantified in vaginal lavage samples, blood plasma containing known amounts of HCV was spiked into lavage samples and was assayed according to the manufacturer's protocol. No inhibition of HCV quantification was detected in vaginal lavage samples.
Nucleotide sequence accession numbers. The C2V3 nucleotide sequences reported in this study have been assigned GenBank accession numbers AF353306-AF353330.
Results

Study Participants
For this analysis, we examined matched samples of cervical mucus, vaginal secretions, and blood plasma from 15 HIV-1-infected women. At the women's first study visits, their CD4 ϩ T lymphocyte counts varied from 35 to 608 cells/mL (median, 296 cells/mL). HIV-1 RNA plasma virus loads ranged from 4900 to 410,000 copies/mL (median, 31,000 copies/mL), whereas vaginal virus loads ranged from !1000 to 430,000 copies/lavage (median, 13,000 copies/lavage). When the samples for this analysis were obtained, none of the women had cervicitis or had tested positive for N. gonorrhoeae, C. trachomatis, or seminal fluid in their genital secretions.
Evidence of Local Viral Replication
To determine whether HIV-1 is replicating in the female genital tract, we assayed for MS HIV-1 mRNA and compared predicted phenotypes and drug resistance-associated mutations of cell-free virus in matched samples of blood plasma and genital secretions.
Detection of cellular viral replication. All 8 cellular vaginal lavage samples tested had ongoing viral replication as shown, using Southern blot analysis, by the presence of MS HIV-1 mRNA-specific, 131-bp PCR product (figure 1B). In these lavage samples, the virus loads ranged from 15,000 to 250,000 copies/lavage (median, 83,000 copies/lavage), and the amounts of MS HIV-1 mRNA and cell-free HIV-1 RNA were highly correlated ( ; ; figure 1C ). r p .76 P p .03 PBMC samples obtained at the same time as the 8 vaginal lavage samples also had MS HIV-1 mRNA (figure 1B). In these samples, the plasma virus loads ranged from 21,000 to 4,500,000 copies/mL (median, 700,000 copies/mL). In contrast to findings in the vaginal lavage samples, the amounts of MS HIV-1 mRNA and cell-free HIV-1 RNA in the blood samples were not correlated ( ; ; figure 1C ). r p .08 P p .85
Comparison of predicted phenotypes of cell-free virus. To investigate possible differences in HIV-1 phenotypes, we compared the predicted amino acid sequences of the C2V3 region in cell-free virus from blood plasma and vaginal secretion samples of 7 HIV-1-infected women (figure 2). The predicted amino acid differences between plasma and vaginal virus for these women were 0.9%, 1.7%, 2.6%, 6.1%, 7.0%, 8.6%, and 9.6%, indicating that, in у4 of the women, the viruses in plasma and vaginal secretions were from different cell populations. In addition, the major species of vaginal HIV-1 for 2 of the women (patients 018 and 022) had a nucleotide insertion or deletion that would cause a frameshift of the amino acid-reading frame and the introduction of multiple missense mutations and premature termination codons. These frameshift mutations did not prevent production of cell-free virus but may have affected infectivity. The major species of plasma HIV-1 from these 2 women did not have the insertion or deletion mutations found in their vaginal viruses.
To investigate whether differences between amino acid sequences of cell-free HIV-1 in blood plasma and genital secretions resulted in differences of predicted cellular tropism, we compared the net charge and signature amino acids in the V3 loop of major HIV-1 species in plasma and genital secretions of 7 HIV-1-infected women (table 1 ). For each sample tested in this study, both the net charge and the signature amino acids in the V3 loop predicted the same cellular tropism. For 5 women, the predicted tropisms were the same for viruses in plasma and genital secretions. However, 2 women (patients 013 and 022) had macrophage-tropic virus in one compartment and T cell-tropic virus in the other, which suggests that the source of the major species of virus in blood was different from that in genital tract secretions.
Comparison of drug resistance-associated mutations. To investigate possible differences in drug resistance, we compared the drug resistance-associated mutations in the RT pol gene of cellfree HIV-1 RNA in matched plasma and vaginal lavage samples obtained from 3 HIV-1-infected women during 8 months of follow-up. These women were using antiretroviral therapy, including у1 RT inhibitor, but viral replication in plasma and in vaginal secretions was not completely suppressed. One of the 3 women NOTE. 3TC, lamivudine; AZT, zidovudine; d4T, stavudine; ddI, didanosine; Idv, indinavir; ND, not determined. a "D69" indicates that the HIV-1 RT enzyme contained the mutant amino acid, aspartic acid (D), at codon 69, which is associated with resistance to RT inhibitors.
"T69" indicates that the RT enzyme contained the wild-type amino acid, threonine (T), at this position. "T/D69" means that a mixture of the wild-type and the mutant amino acids was present, with the wild type predominating. b Patient 011 was not taking antiretroviral medication at her initial visit but had previously used AZT. Her therapy subsequently included AZT, 3TC, and Idv at month 2 of follow-up; Idv at months 3 and 4; d4T and Idv at months 5-7; and d4T, Idv, and ddI at month 8. c "M184" indicates that the HIV-1 RT enzyme contained the wild-type amino acid, methionine (M), at codon 184. "V184" means that the RT enzyme contained the mutant amino acid, valine (V), at this position, which is associated with resistance to lamivudine. "V/M184" means that a mixture of the wild-type and the mutant amino acids was present, with the mutant predominating. "M/V184" means that a mixture of the wild-type and the mutant amino acids was present, with the wild type predominating. d Antiretroviral therapy for patient 001 included AZT and 3TC at her initial visit; AZT, 3TC, and d4T at month 2; AZT alone at month 3; AZT, 3TC, and d4T
at months 4 and 5; and AZT, 3TC, and Idv at months 6-8. had the same drug resistance-associated RT gene mutations in cell-free virus from both plasma and vaginal lavage samples at baseline. However, 2 women had differences between the RT gene mutations in plasma and vaginal lavage samples at baseline (table  2) . During 8 months of follow-up, 1 of these women (patient 011) had a drug resistance-associated mutation in plasma virus that did not appear in vaginal virus, whereas the other woman had a mutation in plasma virus for 6 months before it appeared in vaginal virus.
Lack of Evidence of Plasma Viral Transudation
To determine whether a nonspecific viral transudation mechanism contributes significantly to the HIV-1 load in genital secretions, we examined vaginal lavage samples from women who were infected with both HIV-1 and HCV for the presence of HCV in vaginal secretions. In addition, we compared the C2V3 region in the gp120 envelope of viral RNA in matched samples of blood plasma and genital secretions.
Comparison of plasma and vaginal HCV:HIV-1 ratios. HCV is a small, enveloped RNA virus that replicates primarily in hepatocytes [23] and therefore would be expected in genital secretions only if transudated from blood plasma. If HIV-1 in vaginal secretions is primarily due to transudation or blood contamination, the HCV:HIV-1 ratio in blood plasma and vaginal secretions should be equal. In the 4 women studied, HIV-1 RNA plasma levels ranged from to copies/mL, and 3 5 8.0 ϫ 10 4.4 ϫ 10 HCV RNA levels ranged from to copies/mL 4 5 1.8 ϫ 10 4.5 ϫ 10 (table 3). In 2 women, the HIV-1 and HCV loads in plasma were equivalent. In the other 2 women, the plasma virus load of HCV exceeded that of HIV-1 by 3.4-and 48-fold. In the 2 women with high ratios of HCV load to HIV-1 load in plasma, HIV RNA was detectable in vaginal lavage samples. However, HCV RNA was not detected in any of the 4 lavage samples, which suggests that transudation of plasma virus is not a major source of HIV-1 in vaginal secretions.
Comparison of viral RNA genotypes. We sequenced the major genotypes of HIV-1 RNA in matched blood plasma, vaginal lavage, and cervical mucus samples of 4 HIV-1-infected women (table 4). The median nucleotide difference between the C2V3 sequences of viral RNA in vaginal lavage samples and cervical mucus was 2.2%. In comparison, the median nucleotide difference between plasma and cervical mucus was 3.7%, and the difference between plasma and vaginal secretions was 3.8%. These results indicate that the major species of cell-free HIV-1 in vaginal and cervical secretions are more similar to each other than to the major species found in blood plasma.
Lack of Evidence of Blood Contamination
To determine whether blood contamination contributes significantly to the HIV-1 load in genital secretions, we measured the amount of blood in vaginal lavage and cervical mucus samples, using a quantitative test for hemoglobin [7] . In addition, we compared the C2V3 region of proviral DNA in PBMC with that of viral RNA in matched samples of blood plasma, cervical mucus, and vaginal secretions.
Measurement of blood-derived virus. We have shown previously that HIV-1 RNA from blood contamination may be present in vaginal secretions and cervical mucus but usually appears in low concentrations [7] . In this study, only 1 of 15 vaginal lavage samples tested had 1100 copies of HIV-1 RNA derived from blood, and the blood contribution to vaginal virus load did not exceed 2% in any of the samples.
Comparison of proviral DNA and viral RNA genotypes. It is possible that HIV-1-infected cells from blood populate genital tract tissues and are the major source of cell-free HIV-1 in genital secretions. To address this possibility, we compared the major species of HIV-1 proviral DNA in PBMC with the major species of viral RNA in blood plasma, cervical mucus, and vaginal secretions (table 4) . Previous studies have shown that samples with a !2% nucleotide difference in a variable region of the HIV-1 genome originate from the same source [24] . In 6 (86%) of 7 women tested, the C2V3 region in the gp120 envelope of the major species of PBMC provirus had a !2% nucleotide difference, compared with that of viral RNA in plasma. In 2 women, the C2V3 region in PBMC provirus and plasma viral RNA were identical. However, only 4 (57%) of 7 women had a C2V3 region in PBMC provirus with a !2% nucleotide difference, compared with that in vaginal viral RNA, and none of the women had a C2V3 region in the PBMC provirus identical to that in vaginal virus. In addition, of 4 women tested, none had a C2V3 region in PBMC provirus with a !2% difference, compared with that in cervical virus.
To compare proviral DNA and viral RNA relatedness, we performed a phylogenetic analysis of sequences from the HIV-1-infected women who were included in the genotypic analysis (table 4) . This analysis showed that the HIV-1 sequences from each patient clustered together, compared with those from other patients. In 3 of the 4 women (patients 011, 012, 013, and 022), who had plasma and vaginal HIV-1 RNA nucleotide differences 12% by genotypic analysis, plasma HIV-1 RNA and PBMC proviral DNA were related more closely to each other than to vaginal or cervical HIV-1 RNA (figure 3).
Discussion
In this study, the detection of MS HIV-1 mRNA in vaginal lavage samples indicates that viral replication is occurring in cells in vaginal secretions. MS HIV-1 mRNA, which contains transcripts for viral regulatory trans-acting proteins, is found only in infected cells that are actively replicating virus [25] . At present, the phenotype of the HIV-1-replicating cells in vaginal secretions has not been determined. In this study, sequence analysis of the major proviral species in circulating PBMC, compared with the major viral RNA species in vaginal secretions and cervical mucus, suggests that HIV-1-infected PBMC are not the virus-replicating cells in genital secretions. However, previous studies have shown that macrophages, Langerhans cells, and, to a lesser extent, CD4 ϩ T lymphocytes are shed into vaginal secretions of HIV-1-infected women [26, 27] , and that these cell types are reported to be HIV-1 infected or to sequester the virus in genital tract tissues [28] [29] [30] . In this study, the strong correlation between cellular virus replication and virus load in vaginal lavage samples suggests that local viral replication is the principal source of HIV-1 in vaginal secretions.
In our study, predicted differences in amino acid sequences of cell-free HIV-1 in blood and genital tract secretions provides further evidence that HIV-1 in cervical mucus and vaginal secretions is from local viral replication. Most of the nucleotide differences that we reported between the major species of viral RNA in blood and genital secretions resulted in changes of predicted amino acid residues, which indicates that the differences were not artifacts due to PCR or cycle sequencing. Instead, these differences suggest that locally produced, cell-free HIV-1 in genital secretions was under different selection pressures than that in blood. Local cytokine, chemokine, and HIV-1-specific immunoglobulin production in female genital tract secretions are reported to be different than those in blood [31] [32] [33] [34] [35] and may determine the composition of genital virus populations. Our findings about nucleotide differences between blood and genital secretions extend those of previous studies, which found locale-specific HIV-1 proviral DNA variants in the female genital tract [36] [37] [38] and selected tissues, including seminal fluid, testes, brain, and lung [39] [40] [41] . However, proviral DNA may not represent the population of genomic viral RNA in cell-free virus, since HIV-1-infected cells may contain relatively high levels of latent and defective proviral sequences [42] [43] [44] [45] . Consequently, in our study we focused on analysis of cell-free HIV-1 RNA, as opposed to proviral DNA.
Our analysis of the predicted amino acid sequences of genomic viral RNA indicates that local HIV-1 replication in the female genital tract provides the opportunity for development of virus phenotypes that may be different from those in blood. In our study, predicted cellular tropisms in genital secretions were different than those in blood in 2 (29%) of 7 women. We also found differences in the development of drug resistanceassociated mutations in cell-free HIV-1 in blood, compared with that in genital secretions, which suggests that local HIV-1 replication kinetics or drug availability in the female genital tract may be decreased, compared with that in blood. However, our previous report that the initiation of antiretroviral therapy significantly reduces the amount of HIV-1 RNA simultaneously in blood and vaginal secretions [7] suggests that therapeutic levels of antiretroviral drugs are available in the female genital tract. These results indicate that naturally occurring and therapeutically induced selection pressures occur in the female genital tract independent of those in blood.
Data from our study suggests that blood contamination and plasma transudation are not important sources of HIV-1 in female genital tract secretions. We found no evidence of a viral transudation mechanism capable of transporting another virus, HCV, into vaginal secretions of women who had significant levels of HCV in their blood plasma. HCV in blood plasma is produced primarily in hepatocytes [23] , and its presence in vaginal secretions would require either a transudation mechanism or blood contamination. In women infected with both HIV-1 and HCV, only HIV-1 was detected in vaginal secretions, although the HCV concentration was equal to or greater than the HIV-1 concentration in blood plasma. In addition, we found in this and previous studies [7, 9, 10 ] that blood contamination accounts for !5% of virus load in vaginal secretions in the absence of menstruation. Furthermore, we observed a high percentage of nucleotide differences and greater phylogenetic divergence between HIV-1 sequences in genital secretions and those in blood. These results suggest that blood contamination was not an important source of HIV-1 in the female genital tract.
This report provides new information about the source of HIV-1 in the female genital tract. Our data indicate that cellular replication of HIV-1 occurs in vaginal secretions and that the virus population in these secretions can be significantly different from that in blood. Also, we found that drug resistanceassociated mutations in plasma may not predict resistance-associated mutations in vaginal secretions, which suggests that local viral replication in vaginal secretions is largely independent of viral replication that produces cell-free HIV-1 in blood. Consequently, men infected through heterosexual transmission and infants exposed to the virus during birth may be infected with HIV-1 variants produced in the female genital tract. These findings may have important implications for the development of vaccines to prevent HIV transmission, since successful vaccine strategies will require a thorough understanding of the properties of transmitted viruses.
